A miniaturized 1536-well format γ-secretase assay

Assay and Drug Development Technologies

Volumn 7, Issue 5, 2009, Pages 461-470

  Shelton, Christopher C ^a,b   Tian, Yuan ^a,b   Shum, David ^a   Radu, Constantin ^a   Djaballah, Hakim ^a   Li, Yue Ming ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 OXOCHOLESTERYL ACETATE; ACETIC ACID DERIVATIVE; AMYLOID PRECURSOR PROTEIN; BIOTIN; CISPLATIN; COLISTIN; DIGITONIN; GAMMA SECRETASE; PEPSTATIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; LIBRARY; NONHUMAN; PERFORMANCE MEASUREMENT SYSTEM; VALIDATION PROCESS;

AMYLOID PRECURSOR PROTEIN SECRETASES; AUTOMATION; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HELA CELLS; HUMANS; INDICATORS AND REAGENTS; LUMINESCENCE; MINIATURIZATION;

EID: 70350676657     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0202     Document Type: Article

References (33)

1. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-388.
2. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al.: aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002;3(1):85-97.
3. Goutte C, Tsunozaki M, Hale VA, Priess JR: APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos. Proc Natl Acad Sci USA 2002;99(2):775-779.
4. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, Tandon A, et al.: Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature 2000;407(6800):48-54.
5. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999;398(6727):513-517.
6. Li YM, Lai MT, Xu M, Huang Q, DiMuzio-Mower J, Sardana MK, et al.: Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci USA 2000;97(11):6138-6143.
7. Kopan R, Goate A: A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 2000;14(22):2799-2806.
8. Ni CY, Murphy MP, Golde TE, Carpenter G: gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294(5549):2179-2181.
9. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, et al.: Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abetalike peptide. J Biol Chem 2002;277(47):44754-44759.
10. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, et al.: The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and {gamma}-secretase. Proc Natl Acad Sci USA 2003;100(13):7638-7643.
11. Ikeuchi T, Sisodia SS: The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent "gamma-secretase" cleavage. J Biol Chem 2003;278(10):7751-7754.
12. Harrison T, Churcher I, Beher D: gamma-Secretase as a target for drug intervention in Alzheimer's disease. Curr Opin Drug Discov Dev 2004;7(5):709-719.
13. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, et al.: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435(7044):959-963.
14. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8(1):54-61.
15. Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, et al.: Discovery of Begacestat, a Notch-1-Sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem 2008;51:7348-7351.
16. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, et al.: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 2000;39(30):8698-8704.
17. McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, Lewis PA, et al.: Cellfree assays for gamma-secretase activity. FASEB J 2000;14(15):2383- 2386.
18. Karlstrom H, Bergman A, Lendahl U, Naslund J, Lundkvist J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J Biol Chem 2002;277(9):6763-6766.
19. Bakshi P, Liao YF, Gao J, Ni J, Stein R, Yeh LA, et al.: A high-throughput screen to identify inhibitors of amyloid beta-protein precursor processing. J Biomol Screen 2005;10(1):1-12.
20. Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, et al.: Quantifi cation of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol Med 2000;6(4):291-302.
21. Clarke EE, Shearman MS. Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous time-resolved fl uorescence (HTRF) assay. J Neurosci Methods 2000;102(1):61-68.
22. Szekeres PG, Leong K, Day TA, Kingston AE, Karran EH: Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. J Biomol Screen 2008;13(2):101-111.
23. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM: {gamma}-Secretase substrate concentration modulates the Abeta42/Abeta40 ratio: implications for Alzheimer disease. J Biol Chem 2007;282(32):23639-23644.
24. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4(2):67-73.
25. Ida N, Hartmann T, Pantel J, Schröder J, Zerfass R, Förstl H, et al.: Analysis of heterogeneous A4 peptides in human cerebrospinal fl uid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271(37): 22908-22914.
26. Schatz PJ: Use of peptide libraries to map the substrate specifi city of a peptidemodifying enzyme: a 13 residue consensus peptide specifi es biotinylation in Escherichia coli. Biotechnology (N Y) 1993;11(10):1138-1143.
27. Seiffert D, Bradley JD, Rominger CM, Rominger DH, Yang F, Meredith JE Jr., et al.: Presenilin-1 and -2 are molecular targets for gamma-secretase inhibitors. J Biol Chem 2000;275(44):34086-34091.
28. Beher D, Wrigley JD, Nadin A, Evin G, Masters CL, Harrison T, et al.: Pharmacological knock-down of the presenilin heterodimer by a novel gamma-secretase inhibitor: implications for presenilin biology. J Biol Chem 2001;276(48):45394-45402.
29. Antczak C, Shum D, Escobar S, Bassit B, Kim E, Seshan VE, et al.: High-throughput identifi cation of inhibitors of human mitochondrial peptide deformylase. J Biomol Screen 2007;12(4):521-535.
30. Antczak C, Shum D, Radu C, Seshan VE, Djaballah H: Development and validation of a high-density fl uorescence polarization-based assay for the trypanosoma RNA triphosphatase TbCet1. Comb Chem High Throughput Screen 2009;12(3):258-268.
31. Marciniszyn J, Jr., Hartsuck JA, Tang J: Mode of inhibition of acid proteases by pepstatin. J Biol Chem 1976;251(22):7088-7094.
32. Porcari V, Magnoni L, Terstappen GC, Fecke W: A continuous time-resolved fl uorescence assay for identifi cation of BACE1 inhibitors. Assay Drug Dev Technol 2005;3(3):287-297.
33. Kennedy ME, Wang W, Song L, Lee J, Zhang L, Wong G, et al. Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fl uorescence. Anal Biochem 2003;319(1):49-55.